[go: up one dir, main page]

MX2020008902A - Analogos de compstatina y sus usos medicos. - Google Patents

Analogos de compstatina y sus usos medicos.

Info

Publication number
MX2020008902A
MX2020008902A MX2020008902A MX2020008902A MX2020008902A MX 2020008902 A MX2020008902 A MX 2020008902A MX 2020008902 A MX2020008902 A MX 2020008902A MX 2020008902 A MX2020008902 A MX 2020008902A MX 2020008902 A MX2020008902 A MX 2020008902A
Authority
MX
Mexico
Prior art keywords
compstatin
analogues
introduction
complement
inhibiting activity
Prior art date
Application number
MX2020008902A
Other languages
English (en)
Inventor
Pernille Tofteng Shelton
Jacob Ulrik Fog
Jens Kvist Madsen
Original Assignee
Zp Spv 3 K/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zp Spv 3 K/S filed Critical Zp Spv 3 K/S
Publication of MX2020008902A publication Critical patent/MX2020008902A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/472—Complement proteins, e.g. anaphylatoxin, C3a, C5a
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Psychology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se describen análogos de compstatina que tienen unión y actividad de inhibición del complemento mejoradas en comparación con el péptido de compstatina de 13 aminoácidos (ICVVQDWGHHRCT (C2-C12 cíclico)), en particular análogos de compstatina que adicionalmente poseen propiedades fisicoquímicas útiles, tales como aumento de solubilidad. Estos análogos incluyen variantes con un residuo de isoleucina en la posición 3 en lugar del residuo de valina de tipo natural, que proporciona péptidos de compstatina con unión y actividad de inhibición del complemento mejoradas y también permite la introducción de otras modificaciones, por ejemplo, modificaciones que son capaces de aumentar la solubilidad, tal como la introducción de aminoácidos cargados o polares en la posición 9 y/o la introducción de secuencias de N- y/o C-terminales.
MX2020008902A 2018-02-27 2019-02-26 Analogos de compstatina y sus usos medicos. MX2020008902A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18158834 2018-02-27
EP18214949 2018-12-20
PCT/EP2019/054685 WO2019166411A1 (en) 2018-02-27 2019-02-26 Compstatin analogues and their medical uses

Publications (1)

Publication Number Publication Date
MX2020008902A true MX2020008902A (es) 2020-12-03

Family

ID=65516661

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020008902A MX2020008902A (es) 2018-02-27 2019-02-26 Analogos de compstatina y sus usos medicos.

Country Status (17)

Country Link
US (2) US11965039B2 (es)
EP (1) EP3759120A1 (es)
JP (1) JP7690287B2 (es)
KR (1) KR20200135797A (es)
CN (1) CN112041330B (es)
AU (1) AU2019228639A1 (es)
BR (1) BR112020017385A2 (es)
CA (1) CA3091993A1 (es)
CL (1) CL2020002197A1 (es)
CO (1) CO2020011027A2 (es)
IL (1) IL276877A (es)
MX (1) MX2020008902A (es)
PE (1) PE20201254A1 (es)
RU (1) RU2020128624A (es)
SG (1) SG11202008177WA (es)
TW (1) TW202000686A (es)
WO (1) WO2019166411A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3091993A1 (en) * 2018-02-27 2019-09-06 Zp Spv 3 K/S Compstatin analogues and their medical uses
AU2019247467B2 (en) 2018-04-06 2023-01-19 The Trustees Of The University Of Pennsylvania Compstatin analogs with increased solubility and improved pharmacokinetic properties
US20220306695A1 (en) * 2019-08-27 2022-09-29 Zp Spv 3 K/S Compstatin analogues and their medical uses
CA3177905A1 (en) * 2020-05-15 2021-11-18 Eli Lilly And Company Extended time action acylated insulin compounds
KR20230039718A (ko) * 2020-07-16 2023-03-21 제트피 에스피브이 3 케이/에스 보체 인자 c3의 억제제 및 이들의 의학적 용도
KR20240118914A (ko) 2021-01-20 2024-08-05 바이킹 테라퓨틱스 인코포레이티드 대사 및 간 질환 치료를 위한 조성물 및 방법
KR102873595B1 (ko) 2021-09-15 2025-10-22 바이킹 테라퓨틱스 인코포레이티드 대사 및 간 장애의 치료를 위한 조성물 및 방법
CN120359233A (zh) * 2022-11-24 2025-07-22 阿麦达斯制药美国有限责任公司 用于基于载体的疗法的坎普他汀类似物
CN119219741A (zh) * 2023-06-29 2024-12-31 刘晓蓉 新型补体抑制剂及其制备、应用和产品

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2203197A (en) 1996-03-13 1997-10-01 Trustees Of The University Of Pennsylvania, The Novel peptides which inhibit complement activation
KR100556067B1 (ko) 1996-08-30 2006-03-07 노보 노르디스크 에이/에스 지엘피 - 1 유도체
DE69732640T2 (de) 1996-09-09 2006-01-12 Zealand Pharma A/S Festphasen-peptidsynthese
AU4648197A (en) * 1997-09-17 1999-04-05 Burnham Institute, The Peptides and peptidomimetics for inhibiting complement activation
US6451987B1 (en) 1999-03-15 2002-09-17 Novo Nordisk A/S Ion exchange chromatography of proteins and peptides
CA2361830A1 (en) 1999-03-17 2000-09-21 Novo Nordisk A/S Method for acylating peptides and novel acylating agents
JP4614222B2 (ja) 2002-09-20 2011-01-19 ザ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・ペンシルバニア 改善された活性を有するコンプスタチン（Ｃｏｍｐｓｔａｔｉｎ）類似体
CN101325963B (zh) 2005-10-08 2016-01-27 博泰迪亚制药公司 用于眼部病症的补体抑制素和其类似物
EP2377877B1 (en) 2005-11-28 2018-03-28 The Trustees Of The University Of Pennsylvania Potent compstatin analogs
WO2008153963A1 (en) 2007-06-08 2008-12-18 The Trustees Of The University Of Pennsylvania Structure of compstatin-c3 complex and use for rational drug design
PT2424557T (pt) 2009-05-01 2018-02-05 Univ Pennsylvania Compstatina modificada com estrutura peptídica e modificações no terminal c
US20140113874A1 (en) 2010-09-23 2014-04-24 The Trustees Of The University Of Pennsylvania Modified Compstatin With Improved Stability And Binding Properties
AU2012304442B2 (en) 2011-09-07 2017-05-25 The Trustees Of The University Of Pennsylvania Compstatin analogs with improved pharmacokinetic properties
WO2014078734A2 (en) 2012-11-15 2014-05-22 Apellis Pharmaceuticals, Inc. Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methods
US9512180B2 (en) * 2012-12-19 2016-12-06 The Regents Of The University Of California Compstatin analogs
CA3091993A1 (en) * 2018-02-27 2019-09-06 Zp Spv 3 K/S Compstatin analogues and their medical uses
US20220306695A1 (en) * 2019-08-27 2022-09-29 Zp Spv 3 K/S Compstatin analogues and their medical uses

Also Published As

Publication number Publication date
WO2019166411A1 (en) 2019-09-06
CN112041330A (zh) 2020-12-04
JP7690287B2 (ja) 2025-06-10
CL2020002197A1 (es) 2021-03-05
RU2020128624A (ru) 2022-03-28
SG11202008177WA (en) 2020-09-29
PE20201254A1 (es) 2020-11-16
CN112041330B (zh) 2024-12-27
JP2021515759A (ja) 2021-06-24
EP3759120A1 (en) 2021-01-06
IL276877A (en) 2020-10-29
KR20200135797A (ko) 2020-12-03
US20230192770A1 (en) 2023-06-22
CA3091993A1 (en) 2019-09-06
TW202000686A (zh) 2020-01-01
BR112020017385A2 (pt) 2020-12-15
US20240309046A1 (en) 2024-09-19
US11965039B2 (en) 2024-04-23
CO2020011027A2 (es) 2020-12-10
AU2019228639A1 (en) 2020-09-17

Similar Documents

Publication Publication Date Title
MX2020008902A (es) Analogos de compstatina y sus usos medicos.
MX2022002433A (es) Análogos de compstatina y sus usos médicos.
EP2476698A3 (en) Peptide vaccines for cancers expressing MPHOSPH1 or DEPDC1 polypeptides
BRPI0816405B8 (pt) complexos de rna e pepitídeos catiônicos para transfecção e para imunoestimulação
MX2020010806A (es) Peptidos anti-inflamatorios y usos de los mismos.
EA201691111A1 (ru) Химерные белки фактора viii и их применение
EP3936141A3 (en) Anti-senescence compounds and uses thereof
MX2009012675A (es) Tensioactivos reconstituidos que tienen propiedades mejoradas.
ES2722773T3 (es) Polipéptidos de fHbp meningocócicos modificados
MX2023000679A (es) Inhibidores del factor c3 del complemento y sus usos medicos.
WO2006090810A3 (en) Peptide vaccines for lung cancers expressing ttk, urlc10 or koc1 polypeptides
BR112022012057A2 (pt) Novos métodos de entrega celular
WO2016210370A3 (en) Synthetic peptide compounds and methods of use
MX2025001402A (es) Analogos de compstatina con mayor solubilidad y mejores propiedades farmacocineticas
MY205028A (en) Protein for treatment of inflammatory diseases
MX2021001507A (es) Farmaco de diagnostico y metodo de diagnostico para la enfermedad de alzheimer.
MX2009007261A (es) Vacuna de peptido foxp3.
MX2017016227A (es) Peptidos anti-infecciosos de amplio espectro.
WO2010103515A3 (en) Compositions and methods for prevention and treatment of neurodegenerative diseases
MX2010005816A (es) Epítopos de péptido de stat3.
WO2015110809A3 (en) Drug delivery system
ATE551353T1 (de) Protein mit fusogener wirkung, nukleinsäuresequenzen, die für dieses protein codieren und pharmazeutische zusammensetzungen, die dieses enthalten
BR112022005782A2 (pt) Proteína galectina 9 estabilizada recombinante, vetor recombinante, transformante, composição farmacêutica para prevenção ou tratamento de uma doença óssea, alimento funcional de saúde para prevenção ou melhora de uma doença óssea, e, uso de uma proteína galectina 9 estabilizada recombinante
PH12021551150A1 (en) Transmembrane domain derived from human lrrc24 protein
EP4403566A3 (en) Peptides with vasodilatory and/or diuretic functions